March 22, 2021

Impact Investment in Noile-Immune Biotech, Inc.
- Extending Healthy Life Expectancy through Development and Provision of Next-Generation
Cancer Immunotherapy –The Dai-ichi Life Insurance Company, Limited (the “Company”; President and Representative Director: Seiji Inagaki)
has impact invested JPY 500 million in Noile-Immune Biotech, Inc. ("Noile-Immune"; President & CEO: Koji Tamada), aJapanese startup that develops innovative cancer immunotherapy. This impact investment is a part of the Company's ESG
investments.1
 A startup that develops new drugs focusing mainly on CAR-T cell therapy2 which,among cancer therapies, has been attracting keen attention as the next generation ofcancer therapy
 As a therapy for hematological cancers such as leukemia, CAR-T cell therapy has seen
advanced development, and while it has demonstrated significant therapeutic effects, it
has not been established as a therapy for solid tumorsAn original technology developed by Noile-Immune (PRIME technology)

improves the efficacy of CAR-T cell therapy for solid tumors, and provides a
new therapeutic approach to cancer patients
Social Impact
Realizes an extension of the healthy life expectancy of cancer
Extends the healthy life
expectancy of cancer patientspatients through the development and provision of safe andeffective next-generation cancer immunotherapy for solidtumors

Through this investment, the Company not only expects a high level of returns, but will provide capital support for
Noile-Immune's initiatives, which are expected to extend the healthy life expectancy of cancer patients (social impact).
Further, the Company will continuously monitor the progress of these initiatives.
As a responsible institutional investor, the Company is actively engaged in ESG investment to contribute to realizing
a sustainable society as well as to improve its investment return through sophisticated and diverse investment methods.

1

Impact investment is an investment method where Dai-ichi Life makes investment decisions with the intent to gain investment returns and generate social
impact (e.g., structural change in society).
2
CAR-T cells are cells that are generated by gene transduction technology. They possess the ability to find and attack cancer cells with high specificity
and potency. CAR-T cell therapy was developed as a therapy for hematological cancers, and received pharmaceutical approval in Japan in March 2019.

1

Noile-Immune Biotech, Inc. President & CEO Koji Tamada made the following remarks:
Currently, 1 in 2 people in Japan is diagnosed with cancer, and 1 of every 3 to 4 people dies of cancer.
While many new drugs are being created through advancements in medicine, there are still few safe andhighly effective therapeutic medications for advanced stage cancer, making the development ofrevolutionary cancer treatments an extremely important social task. Noile-Immune Biotech is advancing
research and development with a particular focus on a cutting-edge treatment known as CAR-T celltherapy, a cancer immunotherapy that has been attracting keen attention in recent years. Our originallydeveloped PRIME technology is an innovative technology that may be able to further upgrade CAR-T celltherapy, which to this point has mainly been confirmed to have therapeutic effects for hematologicalcancers, and improve it such that it can demonstrate therapeutic effects for solid tumors, which account forover 90% of cancers. Moving forward, we will develop a pipeline for CAR-T cell therapy utilizing PRIME technology and aim to growas a company that, through the business of creating novel therapeutic medications for cancer, proactively works toward the realization ofan abundant, healthy society.

Company Outline
Trade Name

Noile-Immune Biotech, Inc.

Head Office

T&G Hamamatsu-Cho Building 5F, 2-12-10 Shiba-Daimon, Minato-ku, Tokyo

Representative

Koji Tamada, President & CEO

EstablishedApril 2015Business

Explore innovative cancer immunotherapy based on CAR-T cell Therapy

DescriptionDai-ichi Life's Impact Investment HistoryHeadline

Release
DateURL

Dai-ichi Life to Engage in Impact Investment- First Impact Investment in Gojo & Company, Inc. which provides support for
microfinance business -Oct. 23, 2017https://www.dai-ichilife.co.jp/english/news_release/2017/pdf/ind
ex_012.pdf

Dai-ichi Life to Invest in Spiber Inc.
- Second Impact Investment through Support for Development of New-Generation BioMaterials -Oct. 23, 2017https://www.dai-ichilife.co.jp/company/news/pdf/2017_044.pdf

Dai-ichi Life to Invest in CureApp, Inc.
- Third Impact Investment through Support for Treatment Applications -Feb. 26, 2018https://www.dai-ichilife.co.jp/english/news_release/2017/pdf/index_018.pdf

Dai-ichi Life to Impact Invest in CROWD CREDIT, Inc.
- Energize Business Activities in Developing Countries to Alleviate the Global SupplyDemand Gap for Funds -Apr. 5, 2018https://www.dai-ichilife.co.jp/company/news/pdf/2018_002.pdf

Dai-ichi Life to Impact Invest in SUSMED, Inc.
- Promote the Widespread Adoption of Non-Drug Therapies through Insomnia Therapy
Apps -June 4, 2018https://www.dai-ichilife.co.jp/company/news/pdf/2018_008.pdf

Dai-ichi Life to Impact Invest in MELTIN MMI- Mitigating Accidents Caused by Work in Hazardous Environments by MELTIN’s Avatar
Robots -Oct. 17, 2018https://www.dai-ichilife.co.jp/english/news_release/2018/pdf/ind
ex_004.pdf

Dai-ichi Life to Impact Invest in MOLCURE Inc.
- Shortening Pharmaceutical Development through the World's First Antibody Discovery
Platform Utilizing AI -Nov. 27, 2018https://www.dai-ichilife.co.jp/english/news_release/2018/pdf/ind
ex_007.pdf

2

Dai-ichi Life to Impact Invest in QD Laser, Inc.
- World’s First Eyewear that Employs State-of-the-Art Laser Technology Improves
Quality of Life for Low-Vision Patients -Dec. 12, 2018https://www.dai-ichilife.co.jp/english/news_release/2018/pdf/ind
ex_010.pdf

Dai-ichi Life to Impact Invest in Challenergy Inc.
- Helping to reduce CO2 emissions using the world’s first wind turbine capable ofgenerating electricity even in typhoons -Feb. 28, 2019https://www.dai-ichilife.co.jp/english/news_release/2018/pdf/ind
ex_012.pdf

Dai-ichi Life to Impact Invest in Venture Fund managed by Energy & Environment
Investment, Inc.
- Japan's Only Independent Venture Capital Focused on the Energy and Resource Related
Sectors -Mar. 20, 2019https://www.dai-ichilife.co.jp/english/news_release/2018/pdf/ind
ex_015.pdf

Impact Investment in CureApp and NeuroTrack- Extending healthy life expectancy and improve quality of life through synergies between
investments and life insurance-

July 5, 2019https://www.dai-ichilife.co.jp/english/news_release/2019/pdf/ind
ex_008.pdf

Dai-ichi Life to Impact Invest in Integral Geometry Science- Contributing to a reduction in breast cancer deaths through the world’s first highprecision breast cancer visualizing system -Sep. 13, 2019https://www.dai-ichilife.co.jp/english/news_release/2019/pdf/ind
ex_015.pdf

Dai-ichi Life to Impact Invest in UniFa- Contributing to Resolving the Lengthy Daycare Waiting List Problem Caused by a
Shortage of Nursery Care Workers by Introducing IoT and AI to Daycare Operations -Sep. 27, 2019https://www.dai-ichilife.co.jp/english/news_release/2019/pdf/ind
ex_014.pdf

Dai-ichi Life to Impact Invest in Life is Tech, Inc.
- Contributing to Solving the IT Talent Shortage with IT and Programming Education
Services -Nov. 15, 2019https://www.dai-ichilife.co.jp/english/news_release/2019/pdf/ind
ex_018.pdf

Dai-ichi Life to Impact Invest in World's First Anti-Smoking Social Impact Bond
- Support Social Impact Creator and Investment Recipient CureApp, through Investment
in Anti-Smoking Project -Nov. 29, 2019https://www.dai-ichilife.co.jp/english/news_release/2019/pdf/ind
ex_021.pdf

Dai-ichi Life to Impact Invest in Modulus Discovery, Inc.
- Contributing to Realizing Accessible Healthcare for All by Cutting Development
Timelines and Costs of Pharmaceuticals -May 13, 2020

https://www.dai-ichilife.co.jp/english/news_release/2020/pdf/ind
ex_003.pdf

Impact Investment in Metcela Inc.
- Contributing to Extending Healthy Life Expectancy of Patients with Heart Failure
through the Development and Provision of a New Treatment -Jan. 4, 2021

https://www.dai-ichilife.co.jp/english/news_release/2020/pdf/ind
ex_017.pdf

Impact Investment in Sharing Energy Co., Ltd.
- Contributing to CO2 emission reduction through distributed renewable energy power
generation for residential solar power -Feb. 15, 2021

https://www.dai-ichilife.co.jp/english/news_release/2020/pdf/ind
ex_021.pdf

Impact Investment in GITAI Japan- Contributing to Economic Growth through Promotion of Space Development by Meansof R&D for Space Worker Robots -March 1, 2021

https://www.dai-ichilife.co.jp/english/news_release/2020/pdf/ind
ex_024.pdf

3